Abstract: A stable pharmaceutical composition comprising a) a therapeutically effective amount of an Angiotensin Converting Enzyme (“ACE”) inhibitor which is susceptible to degradation or its salt; b) a greater than stoichiometric amount of an alkali or alkaline earth metal carbonate, relative to the amount of ACE inhibitor or its salt; and c) a pharmaceutically acceptable carrier, including a process for the manufacture of such compositions.

Abstract: Pharmaceutical capsule dosage forms of benzimidazole proton pump inhibitors are prepared by enclosing one or several enteric coated compressed cores in a capsule shell. The inventive formulations are stable and have higher bioavailability of the active ingredient relative to pellet and granule containing formulations.

Abstract: A solid dosage form having a fill composition encased in a shell composition; the fill composition comprising(a) 5-60 mg of nifedipine;(b) a 5-7 membered cyclic pharmaceutically acceptable ingestible carbonate of the formula ##STR1## where A is an alpha,omega-C.sub.2 -C.sub.4 alkylene which is unsubstituted or substituted by at least one C.sub.1 -C.sub.4 alkyl; and(c) a pharmaceutically acceptable ingestible surfactant having a total of d ring members and being of the formula ##STR2## wherein B is a C.sub.1-4 -alpha,omega-alkylene;n is an integer from 0 up to d-1;m is an integer from 0 up to (d-n-1);each R is independently H or a C.sub.1-4 alkyl which is unsubstituted or substituted by at least one R';each R' is independently a hydroxy which is free, etherified by R.sup.2, or esterified by R.sup.3 ;each R.sup.2 is a C.sub.2-4 straight or branched oxyalkylene or a poly (C.sub.2-4 straight or branched oxyalkylene), the terminal oxygen of which is bound to hydrogen or R.sup.3 ; and each R.sup.